Automated Clinical Pathway for Inflammatory Bowel Disease Care

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

1000 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-12-12

Study Completion Date

2026-12-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Pragmatic randomized controlled trial to evaluate the effect of an electronic medical record-based tool on improving on-time follow up and its effects on inflammatory bowel disease outcomes

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Patient Attitudes and Preferences for Outcomes of Inflammatory Bowel Disease Therapeutics

NCT02316678

Colitis, Ulcerative Inflammatory Bowel Diseases Crohn's Disease

COMPLETED

Feasibility Pilot Sequential Multiple Assignment Randomized Trial (SMART) for Acute Severe Ulcerative Colitis

NCT05867329

Ulcerative Colitis Acute

RECRUITING PHASE4

MyChart in Patients With Inflammatory Bowel Disease.

NCT03241992

Inflammatory Bowel Diseases

COMPLETED NA

Personalised Prediction of Disease Course in Ulcerative Colitis Using Multimodal Machine Learning - Part of the Presager Project

NCT05479617

Ulcerative Colitis

RECRUITING

Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

NCT05230173

Ulcerative Colitis Crohn Disease

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Disease Inflammatory Bowel Disease (IBD)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

HEALTH_SERVICES_RESEARCH

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Care pathway arm

Use of an electronic medical record-based, risk-stratified tool that automates the identification of patients who are overdue for follow up and facilitates a proactive scheduling plan

Group Type EXPERIMENTAL

Electronic medical record-based care pathway

Intervention Type OTHER

Participants will undergo initial automated risk stratification to direct tailored follow-up intervals. If exceeding the maximum time interval, participants in the intervention arm will be contacted by scheduling personnel using a standardized protocol to schedule a follow-up visit. In contrast, patients in the control arm who are overdue will not be made known to any staff and will not be proactively contacted, instead continuing to be managed according to standard of care. To maximize generalizability and understanding among staff and patients, risk stratification will be based on inflammatory bowel disease medication use.

Usual care

Standard disease management, monitoring, and follow-up as directed by clinical team

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Electronic medical record-based care pathway

Participants will undergo initial automated risk stratification to direct tailored follow-up intervals. If exceeding the maximum time interval, participants in the intervention arm will be contacted by scheduling personnel using a standardized protocol to schedule a follow-up visit. In contrast, patients in the control arm who are overdue will not be made known to any staff and will not be proactively contacted, instead continuing to be managed according to standard of care. To maximize generalizability and understanding among staff and patients, risk stratification will be based on inflammatory bowel disease medication use.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Alive patients with 2 or more visits to the UT Southwestern adult digestive disease clinic within 3 years of the date of trial commencement including at least one visit within 2 years, and
2. An active inflammatory bowel disease-specific medication, and
3. At least one of the following:

1. Inflammatory bowel disease on the active problem list
2. An inflammatory bowel disease invoice diagnosis at least twice in the 3 years prior to trial commencement
3. An inflammatory bowel disease encounter diagnosis at least twice in the 3 years prior to trial commencement

Eligible Sex

ALL

Accepts Healthy Volunteers

No